Type 2 Diabetic Medication Regimen in Treating Depression and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Veterans Using PHQ-9 and FIB-4 Scores

被引：0
|
作者：
Ubalde, Shannen Nicole
Khoury, Jessica
Davis, Jessica
Sen, Sabyasachi
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-1889-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1889-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Metabolic dysfunction-associated steatotic liver disease prevalence and predictors in patients with type 2 diabetes in primary care
    Balkhed, Wile
    Nasr, Patrik
    Cai, Shan
    Simonsson, Christian
    Forsgren, Mikael
    Bergram, Martin
    Leinhard, Olof Dahlqvist
    Dahlstrom, Nils
    Carlhall, Carl-Johan
    Lundberg, Peter
    Radholm, Karin
    Iredahl, Fredrik
    Kechagias, Stergios
    Ekstedt, Mattias
    JOURNAL OF HEPATOLOGY, 2024, 80 : S532 - S532
  • [42] Association between metabolic dysfunction-associated steatotic liver disease and ischemic stroke in patients with type 2 diabetes
    Jang, M.
    Kim, G.
    Lee, K. -N.
    Han, K.
    Oh, R.
    Cho, S.
    Kim, J.
    Lee, Y. -B.
    Jin, S. -M.
    Hur, K.
    Kim, J.
    DIABETOLOGIA, 2024, 67 : S98 - S98
  • [43] Editorial: Evaluating the Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinemia
    Bhardwaj, Nakul J.
    Kim, Rebecca G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (04) : 727 - 728
  • [44] Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Patients-The Relationship with Platelets Indicators
    Onisor, Danusia
    Roiban, Andrada Larisa
    Cernea, Simona
    MEDICINA-LITHUANIA, 2024, 60 (12):
  • [45] Exercise in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is Associated With Better Metabolic Profile and Higher Scores for Patient Reported Outcomes (PROs): Data From the Global NASH/MASH Registry
    Alqahtani, Saleh A.
    Stepanova, Maria M.
    Alahamed, Reem
    Henry, Linda
    Racila, Andrei
    Nader, Fatema
    Eguchi, Yuichiro
    Yilmaz, Yusuf
    Mohammed, Manal
    Younossi, Zobair
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1289 - S1289
  • [46] Poor Performance of FIB-4 in Fibrosis Prediction for Chronic Hepatitis B Patients with Metabolic Dysfunction-Associated Liver Disease in Daily Clinical Practice
    Abu Baker, Fadi
    Abu Mouch, Saif
    Nicola, Dorin
    Taher, Randa
    JOURNAL OF HEPATOLOGY, 2024, 80 : S789 - S789
  • [47] Fibrosis-4 score for screening of metabolic dysfunction-associated steatotic liver disease (MASLD): Data from a population-based sample in Tuscany
    Silverii, Giovanni Antonio
    Profili, Francesco
    Francesconi, Paolo
    Mannucci, Edoardo
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2024, 34 (10) : 2405 - 2408
  • [48] New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Stratina, Ermina
    Stanciu, Carol
    Nastasa, Robert
    Zenovia, Sebastian
    Stafie, Remus
    Rotaru, Adrian
    Cuciureanu, Tudor
    Muzica, Cristina
    Sfarti, Catalin
    Girleanu, Irina
    Minea, Horia
    Petrea, Oana
    Huiban, Laura
    Chiriac, Stefan
    Singeap, Ana-Maria
    Vlad, Oana
    Cojocariu, Camelia
    Trifan, Anca
    DIAGNOSTICS, 2024, 14 (14)
  • [49] Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease
    Qi, Xiaolong
    Li, Jie
    Caussy, Cyrielle
    Teng, Gao-Jun
    Loomba, Rohit
    HEPATOLOGY, 2024,
  • [50] Increased Prevalence of Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease Fibrosis in Type 2 Diabetics Despite Low-Risk Fibrosis-4 Index Scores
    Woodard, Jordan S.
    Abrams, Gary A.
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2024, 14 (01) : 40 - 47
12345